SPPI · Spectrum Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | - | $128.37M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $42.20M | $87.30M | $109.38M | $79.33M | $94.96M | $65.89M |
| SG&A | $38.82M | $60.41M | $60.36M | $61.37M | $90.70M | $84.27M |
| Total Operating Expenses | $82.81M | $147.70M | $169.73M | $140.70M | $240.51M | $225.03M |
| D&A | $248.0K | $286.0K | $261.0K | $1.62M | $28.41M | $27.97M |
| Operating Income | ($72.70M) | ($147.70M) | ($169.73M) | ($140.70M) | ($131.18M) | ($96.66M) |
| Interest Expense | - | - | - | - | $3.13M | $8.07M |
| Income Tax | $46.0K | $4.0K | ($60.0K) | ($9.21M) | $1.0K | ($16.78M) |
| Net Income | ($75.40M) | ($158.63M) | ($160.87M) | ($112.69M) | ($120.01M) | ($91.25M) |
| EPS - Basic | ($0.41) | ($1.29) | - | - | ($1.16) | ($1.07) |
| EPS - Diluted | ($0.41) | ($1.29) | - | - | ($1.16) | ($1.07) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.37M | $88.54M | $46.01M | $64.42M | $157.48M | $227.32M |
| Accounts Receivable | $13.00M | $0 | $67.0K | $441.0K | $29.87M | $32.26M |
| Inventory | $9.23M | - | - | - | $3.55M | $5.71M |
| Accounts Payable | $30.55M | $33.41M | $34.38M | $32.01M | $44.92M | $33.65M |
| Current Assets | $101.01M | $103.95M | $186.65M | $244.02M | $250.69M | $277.75M |
| Total Assets | $103.34M | $111.55M | $196.80M | $263.43M | $390.89M | $487.44M |
| Current Liabilities | $42.69M | $53.23M | $53.15M | $61.97M | $86.47M | $109.75M |
| Long-term Debt | $28.67M | - | - | - | - | - |
| Total Liabilities | $75.45M | $63.99M | $62.55M | $73.04M | $107.62M | $136.10M |
| Stockholders' Equity | $27.89M | $47.55M | $134.24M | $190.39M | $283.26M | $351.34M |
| Retained Earnings | ($1.12B) | ($1.04B) | ($885.29M) | ($724.43M) | ($599.89M) | ($502.11M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($96.99M) | ($119.49M) | ($121.63M) | ($134.63M) | ($62.40M) | ($38.85M) |
| Investing Cash Flow | ($26.72M) | $108.71M | $18.07M | $31.99M | $1.37M | ($1.08M) |
| Financing Cash Flow | $75.59M | $53.31M | $85.23M | $9.63M | ($8.46M) | $108.72M |
| CapEx | $273.0K | $221.0K | $5.54M | $9.02M | $107.0K | $465.0K |
| Free Cash Flow | ($97.26M) | ($119.71M) | ($127.16M) | ($143.65M) | ($62.51M) | ($39.32M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -75.3% |
| EBITDA margin | - | - | - | - | - | -53.5% |
| Net margin | - | - | - | - | - | -71.1% |
| Free cash flow margin | - | - | - | - | - | -30.6% |
| FCF / Net income | 1.29 | 0.75 | 0.79 | 1.27 | 0.52 | 0.43 |
| R&D / Revenue | - | - | - | - | - | 51.3% |
| SG&A / Revenue | - | - | - | - | - | 65.6% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -73.0% | -142.2% | -81.7% | -42.8% | -30.7% | -18.7% |
| Return on equity | -270.4% | -333.6% | -119.8% | -59.2% | -42.4% | -26.0% |
| Return on invested capital | -101.6% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.37 | 1.95 | 3.51 | 3.94 | 2.90 | 2.53 |
| Quick ratio | 2.15 | 1.95 | 3.51 | 3.94 | 2.86 | 2.48 |
| Cash ratio | 0.95 | 1.66 | 0.87 | 1.04 | 1.82 | 2.07 |
| Leverage | ||||||
| Debt / Equity | 1.03 | - | - | - | - | - |
| Debt / Assets | 0.28 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -41.9x | -12.0x |
| Equity multiplier | 3.71 | 2.35 | 1.47 | 1.38 | 1.38 | 1.39 |
| Liabilities / Assets | 0.73 | 0.57 | 0.32 | 0.28 | 0.28 | 0.28 |
| Efficiency | ||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | - | 0.26 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 92d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | -12.3% |
| Revenue CAGR (3y) | - | - | - | - | - | -11.8% |
| Revenue CAGR (5y) | - | - | - | - | - | -13.7% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 50.8% | 13.0% | -20.6% | -7.3% | -35.7% | -56.8% |
| Net income growth (YoY) | 52.5% | 1.4% | -42.8% | 6.1% | -31.5% | -33.2% |
| EPS growth (YoY) | 68.2% | - | - | - | -8.4% | -13.8% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 18.7% | 5.9% | 11.5% | -129.8% | -59.0% | 3.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -41.4% | -64.6% | -29.5% | -32.8% | -19.4% | 48.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2019-12-31.
Product / service
$700.0K totalService$700.0K · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-10.80
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SPECTRUM PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.